Abstract
The effects of ionising radiation on the development of cutaneous squamous cell carcinoma have been previously studied in environments in which the levels of ionising radiation have been increased by artificial sources. The purpose of this study is to determine the role that environmental radon concentration and natural gamma radiation emissions may play in the development of head and neck cutaneous squamous cell carcinoma in a geographical area which is known to have high levels of radon and natural terrestrial gamma radiation emissions. A total of 284 patients diagnosed with cutaneous squamous cell carcinoma during the 26-month observation period were included in the study. The overall incidence was 37.33 cases/100,000 people-year. The mean of environmental radon concentration according to their council of residence was 116.69 Bq/m3 (40.05) and the mean of natural terrestrial gamma radiation emitted according to their council of residence was 14.25 μRad/hour (3.86). The multiple linear regression analysis revealed that only mean natural terrestrial gamma radiation emissions in the council of residence (P < 0.05), carrying out an outdoor profession (P < 0.05) and the mean number of hours of sunlight per year in the council of residence (P = 0.03) were found to have statistical significance on the incidence of head and neck cutaneous squamous cell carcinoma. Emissions of natural terrestrial gamma radiation have never been proposed as a factor having an influence on the development of cutaneous neoplasms. The implications that this could have in areas with naturally high terrestrial gamma radiation emissions should be more exhaustively studied to assess the true weight of this factor.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Regional Ethics Committee. Rede Galega de Comités de Ética da Investigación (CEImG). Comité de Etica da Investigación de Santiago-Lugo.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data cannot be shared publicly because of we are working with private clinical features obtained from medical records.
